SynapDx Corporation, a Southborough, Mass.-based developer of diagnostic test designed to identify children with autism spectrum disorders (ASD) by age 36 months, secured $2m in funding from Laboratory Corporation of America® Holdings (NYSE: LH).
Founded in 2010 and led by Stanley Lapidus, CEO, SynapDx leverages collaborations with ASD experts at leading institutions, including Boston Children’s Hospital, to build a broad pediatric neurodevelopment testing offering.
The investment, which follows a $6m round (read here), will support the clinical development of the company’s blood-based autism spectrum disorder (ASD) diagnostic test, designed to help clinicians improve diagnosis and identify autism in children earlier than they do today.
FinSMEs
21/02/2013